Statement of Changes in Beneficial Ownership (4)
December 03 2021 - 06:56PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
| 1. Name
and Address of Reporting Person *
Azamian Bobak R. |
2. Issuer Name and Ticker or Trading
Symbol Tarsus Pharmaceuticals, Inc. [ TARS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)__X__
Director _____
10% Owner
__X__ Officer (give title
below) _____ Other
(specify below)
President and CEO |
|
(Last)
(First)
(Middle)
C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD,
SUITE 160 |
3. Date of Earliest Transaction (MM/DD/YYYY)
12/1/2021
|
|
(Street)
IRVINE, CA 92618
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
Amount |
(A) or (D) |
Price |
|
Common Stock |
12/1/2021 |
|
S(1) |
|
2394 |
D |
$23.86 (2) |
1207545 |
I |
By the Bobak Azamian Living Trust established
April 16, 2018 (3) |
|
Common Stock |
12/1/2021 |
|
S(1) |
|
2101 |
D |
$24.70 (4) |
1205444 |
I |
By the Bobak Azamian Living Trust established
April 16, 2018 (3) |
|
Common Stock |
12/1/2021 |
|
S(1) |
|
760 |
D |
$25.90 (5) |
1204684 |
I |
By the Bobak Azamian Living Trust established
April 16, 2018 (3) |
|
Common Stock |
12/1/2021 |
|
S(1) |
|
578 |
D |
$26.76 (6) |
1204106 |
I |
By the Bobak Azamian Living Trust established
April 16, 2018 (3) |
|
Common Stock |
|
|
|
|
|
|
|
1750 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
| Explanation of
Responses: |
| (1) |
The sales reported in this
Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1
trading plan adopted by the Reporting Person on May 14,
2021. |
| (2) |
The price reported in column
4 is a weighted average price. The shares were pooled and sold in
multiple transactions at prices ranging from $23.28 to $24.22. The
Reporting Person undertakes to provide to the Issuer, any security
holder of the Issuer, or the staff of the Securities and Exchange
Commission, upon request, full information regarding the number of
shares sold at each separate price within the range set forth in
this footnote. |
| (3) |
The Reporting Person is the
trustee of the Bobak Azamian Living Trust, established April 16,
2018 and has voting and dispositive power with respect to these
shares. |
| (4) |
The price reported in column
4 is a weighted average price. The shares were pooled and sold in
multiple transactions at prices ranging from $24.3 to $25.28. The
Reporting Person undertakes to provide to the Issuer, any security
holder of the Issuer, or the staff of the Securities and Exchange
Commission, upon request, full information regarding the number of
shares sold at each separate price within the range set forth in
this footnote. |
| (5) |
The price reported in column
4 is a weighted average price. The shares were pooled and sold in
multiple transactions at prices ranging from $25.33 to $26.26. The
Reporting Person undertakes to provide to the Issuer, any security
holder of the Issuer, or the staff of the Securities and Exchange
Commission, upon request, full information regarding the number of
shares sold at each separate price within the range set forth in
this footnote. |
| (6) |
The price reported in column
4 is a weighted average price. The shares were pooled and sold in
multiple transactions at prices ranging from $26.57 to $27.19. The
Reporting Person undertakes to provide to the Issuer, any security
holder of the Issuer, or the staff of the Securities and Exchange
Commission, upon request, full information regarding the number of
shares sold at each separate price within the range set forth in
this footnote. |
Reporting
Owners
|
|
Reporting Owner Name / Address |
Relationships
|
|
Director |
10% Owner |
Officer |
Other |
Azamian Bobak R.
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160
IRVINE, CA 92618 |
X |
|
President and CEO |
|
Signatures
|
|
/s/ Leonard M. Greenstein,
Attorney-in-Fact |
|
12/3/2021 |
| **Signature of
Reporting Person |
Date |
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From Apr 2022 to May 2022
Tarsus Pharmaceuticals (NASDAQ:TARS)
Historical Stock Chart
From May 2021 to May 2022
